Dr. Ishizuka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-688-4242
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2019- Brigham and Women's HospitalResidency, Internal Medicine, 2014 - 2015
- Brigham and Women's HospitalInternship, Internal Medicine, 2013 - 2014
Harvard Medical SchoolClass of 2012
Certifications & Licensure
CT State Medical License 2020 - 2025
MA State Medical License 2013 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1093 citationsSubsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.Brian C. Miller, Debattama R. Sen, Rose Al Abosy, Kevin Bi, Yamini V. Virkud
Nature Immunology. 2019-02-18 - 179 citationsEpigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicityGabriel K. Griffin, Jingyi Wu, Arvin Iracheta-Vellve, James C Patti, Jeffrey Hsu
Nature. 2021-05-05 - 409 citationsLoss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.Jeffrey J. Ishizuka, Robert T. Manguso, Collins K. Cheruiyot, Kevin Bi, Arpit Panda
Nature. 2019-01-01
Press Mentions
Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
